Contents

Search

ertugliflozin/sitagliptin (Steglujan)

Indications: - treatment of diabetes mellitus type 2 Dosage: Tabs: ertugliflozin/sitagliptin 5 mg/100 mg, 15 mg/100 mg

Interactions

drug adverse effects of hypoglycemic agents

General

hypoglycemic combination

References

  1. Busko M FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes Medscape - Dec 21, 2017. https://www.medscape.com/viewarticle/890446